Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141074 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
A Phase 3 study of Congenital Bleeding Disorder and Haemophilia B, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
- 20
- Study locations
NCT02141074 is a Phase 3 study of Congenital Bleeding Disorder and Haemophilia B that has completed, run by Novo Nordisk A/S. The registered enrollment target is 54 participants, below the 132-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02141074, a Phase 3 study of Congenital Bleeding Disorder and Haemophilia B, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
Conditions Studied
Interventions
- DRUG nonacog beta pegol
Study Locations (20)
California
- Miller Children's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
Florida
- Shands Hospital at the University of Florida - Gainesville
- Nemours Chld Clnc Jacksonville - Jacksonville
Georgia
- Augusta University - Augusta
- Hope for Kids - Macon
North Carolina
- University of North Carlolina-Chapel Hill - Chapel Hill
- Novant Hlth Vasc Ins Charlotte - Charlotte
Ohio
- Univ Hosp Cleveland Med Ctr - Cleveland
- Dayton Children Hemostati Ctr - Dayton
Pennsylvania
- Penn State MS Hershey Med Ctr - Hershey
- St Christopher Hosp for Child - Philadelphia
Idaho
- St. Luke's Mountain States Tumor Institute - Boise
Iowa
- University Of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-07-02 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141074
The ClinicalTrials.gov registry entry for NCT02141074 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (59% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which nonacog beta pegol is the first listed.
NCT02141074 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02141074 about?
NCT02141074 is a clinical study titled "Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B". This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
What is the current status of trial NCT02141074?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2014-07-02. Estimated completion is 2022-10-27.
What conditions does trial NCT02141074 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia B.
What interventions are being tested in trial NCT02141074?
The interventions under investigation include: nonacog beta pegol (DRUG).
Who is sponsoring clinical trial NCT02141074?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141074 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
COMPLETED · Phase 3
-
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
COMPLETED · Phase 3
-
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
COMPLETED · Phase 3
-
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.